2023
Dynamics of chikungunya virus transmission in the first year after its introduction in Brazil: A cohort study in an urban community
Anjos R, Portilho M, Jacob-Nascimento L, Carvalho C, Moreira P, Sacramento G, Nery N, de Oliveira D, Cruz J, Cardoso C, Argibay H, Plante K, Plante J, Weaver S, Kitron U, Reis M, Ko A, Costa F, Ribeiro G. Dynamics of chikungunya virus transmission in the first year after its introduction in Brazil: A cohort study in an urban community. PLOS Neglected Tropical Diseases 2023, 17: e0011863. PMID: 38150470, PMCID: PMC10775974, DOI: 10.1371/journal.pntd.0011863.Peer-Reviewed Original ResearchAge-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose
Filardi B, Monteiro V, Schwartzmann P, do Prado Martins V, Zucca L, Baiocchi G, Malik A, Silva J, Hahn A, Chen N, Pham K, Pérez-Then E, Miric M, Brache V, Cochon L, Larocca R, Della Rosa Mendez R, Silveira D, Pinto A, Croda J, Yildirim I, Omer S, Ko A, Vermund S, Grubaugh N, Iwasaki A, Lucas C, Initiative Y, Vogels C, Breban M, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W. Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose. Science Translational Medicine 2023, 15: eade6023. PMID: 36791210, DOI: 10.1126/scitranslmed.ade6023.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, ViralAntibody FormationBNT162 VaccineCOVID-19HumansImmunoglobulin GSARS-CoV-2ConceptsBooster doseAntibody responseNeutralization titersVirus-specific IgG titersOlder adultsAntiviral humoral immunityPlasma antibody responsesHigh-risk populationSARS-CoV-2 spikeYears of ageAge-dependent impairmentHeterologous regimensBooster dosesBooster vaccineCoronaVac vaccineIgG titersProtective immunityHumoral immunityHumoral responseCoronaVacOmicron waveBooster strategyAge groupsEarly controlVaccine
2022
Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey
Fofana MO, Nery N, Ticona J, de Andrade Belitardo EMM, Victoriano R, Anjos RO, Portilho MM, de Santana MC, dos Santos LL, de Oliveira D, Cruz JS, Muenker MC, Khouri R, Wunder EA, Hitchings MDT, Johnson O, Reis MG, Ribeiro GS, Cummings DAT, Costa F, Ko AI. Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey. PLOS Medicine 2022, 19: e1004093. PMID: 36074784, PMCID: PMC9499230, DOI: 10.1371/journal.pmed.1004093.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionSARS-CoV-2 infection riskUrban slumsSyndrome coronavirus 2 infectionSARS-CoV-2 seroprevalenceSARS-CoV-2 incidenceCoronavirus 2 infectionCross-sectional serosurveyMain outcome measuresUrban slum populationPresence of IgGSARS-CoV-2 spike proteinUrban slum communityCross-sectional surveyUrban slum residentsCumulative incidenceMedian ageRisk factorsOutcome measuresStudy populationHigh seroprevalenceMedian dailyPandemic waveGender distributionReliable estimation of SARS-CoV-2 anti-spike protein IgG titers from single dilution optical density values in serologic surveys
Belitardo E, Nery N, Ticona J, Portilho MM, Mello IO, Ribeiro GS, Reis MG, Costa F, Cummings DAT, Ko AI, Fofana MO. Reliable estimation of SARS-CoV-2 anti-spike protein IgG titers from single dilution optical density values in serologic surveys. Diagnostic Microbiology And Infectious Disease 2022, 104: 115807. PMID: 36162285, PMCID: PMC9428330, DOI: 10.1016/j.diagmicrobio.2022.115807.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralCOVID-19HumansImmunoglobulin GReproducibility of ResultsSARS-CoV-2Seroepidemiologic StudiesConceptsSARS-CoV-2 incidenceCommunity-based cohortPopulation-level immunitySARS-CoV-2Large-scale serosurveysELISA optical densityIgG titersIgG ELISAPandemic evolvesSerologic surveyTitersOptical density valuesPopulation-level changesSerosurveyImmunitySingle dilutionSerial dilutionsNODCohortIncidenceELISASerum
2021
Delayed production of neutralizing antibodies correlates with fatal COVID-19
Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, Mao T, Oh JE, Mohanty S, Huang J, Tokuyama M, Lu P, Venkataraman A, Park A, Israelow B, Vogels CBF, Muenker MC, Chang CH, Casanovas-Massana A, Moore AJ, Zell J, Fournier JB, Wyllie A, Campbell M, Lee A, Chun H, Grubaugh N, Schulz W, Farhadian S, Dela Cruz C, Ring A, Shaw A, Wisnewski A, Yildirim I, Ko A, Omer S, Iwasaki A. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine 2021, 27: 1178-1186. PMID: 33953384, PMCID: PMC8785364, DOI: 10.1038/s41591-021-01355-0.Peer-Reviewed Original ResearchConceptsDeceased patientsAntibody levelsAntibody responseDisease severityAnti-S IgG levelsCOVID-19 disease outcomesFatal COVID-19Impaired viral controlWorse clinical progressionWorse disease severitySevere COVID-19Length of hospitalizationImmunoglobulin G levelsHumoral immune responseCoronavirus disease 2019COVID-19 mortalityCOVID-19Domain (RBD) IgGSeroconversion kineticsDisease courseIgG levelsClinical parametersClinical progressionHumoral responseDisease onset
2020
Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study
Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, Massey DS, Dugan A, Witters D, Marlar J, Li SX, Lin Z, Hodge D, Chattopadhyay M, Adams MD, Lee C, Rao LV, Stewart C, Kuppusamy K, Ko AI, Krumholz HM. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. The American Journal Of Medicine 2020, 134: 526-534.e11. PMID: 33130124, PMCID: PMC7598362, DOI: 10.1016/j.amjmed.2020.09.024.Peer-Reviewed Original ResearchConceptsSARS-CoV-2-specific IgG antibodiesWeighted seroprevalenceIgG antibodiesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2-specific antibodiesConnecticut residentsSelf-reported adherenceImmunoglobulin G antibodiesSARS-CoV-2Symptomatic illnessSerology testingSeroprevalence studyG antibodiesPrevalence studyGeneral populationPercentage of peopleSeroprevalenceLack antibodiesMajority of respondentsAntibodiesHispanic subpopulationsConvenience sampleHispanic populationCOVID-19Risk mitigation behaviors
2019
Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region
Rodriguez-Barraquer I, Costa F, Nascimento EJM, Nery N, Castanha PMS, Sacramento GA, Cruz J, Carvalho M, De Olivera D, Hagan JE, Adhikarla H, Wunder EA, Coêlho DF, Azar SR, Rossi SL, Vasilakis N, Weaver SC, Ribeiro GS, Balmaseda A, Harris E, Nogueira ML, Reis MG, Marques ETA, Cummings DAT, Ko AI. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science 2019, 363: 607-610. PMID: 30733412, PMCID: PMC8221194, DOI: 10.1126/science.aav6618.Peer-Reviewed Original ResearchConceptsZika virusZIKV NS1 antigenAttack rateZika virus emergenceHigh antibody titersDengue-endemic regionsZIKV immunityClinical outcomesDengue immunityZIKV infectionAntibody titersNS1 antigenRisk factorsEndemic regionsDengue virusImmunityVirusRiskVirus emergenceFuture transmissionCohortSymptomsInfectionAntigenTiters
2001
Evaluation of Recombinant Leptospira Antigen-Based Enzyme-Linked Immunosorbent Assays for the Serodiagnosis of Leptospirosis
Flannery B, Costa D, Carvalho F, Guerreiro H, Matsunaga J, Da Silva E, Ferreira A, Riley L, Reis M, Haake D, Ko A. Evaluation of Recombinant Leptospira Antigen-Based Enzyme-Linked Immunosorbent Assays for the Serodiagnosis of Leptospirosis. Journal Of Clinical Microbiology 2001, 39: 3303-3310. PMID: 11526167, PMCID: PMC88335, DOI: 10.1128/jcm.39.9.3303-3310.2001.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayIgG enzyme-linked immunosorbent assaySerodiagnosis of leptospirosisHealthy individualsImmunosorbent assayTest-positive individualsCases of leptospirosisHigh-incidence regionsLyme disease patientsMicroscopic agglutination testConvalescent phaseHepatitis patientsAcute phaseDengue patientsDisease patientsPatient seraHealthy residentsLeptospira antigensCutoff valueDiagnostic utilityPatientsAgglutination testUseful antigenLeptospirosisAntigen